Industrial application Clause Samples

Industrial application. An invention shall be considered as susceptible of industrial application if it can be made or used in any kind of industry, including agriculture

Industrial application. (1) Subject to subsection (2) below, an invention shall be taken to be capable of industrial application if it can be made or used in any kind of industry, including agriculture. The Myriad Genetics Controversy Among the genes associated with breast and ovarian cancer are: Competition between researchers The major research teams working to locate BRCA1 and BRCA2 included: • USA - ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇'▇ group and ▇▇▇▇ ▇▇▇▇▇▇▇▇'▇ group • UK- the main group were associated with ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇, and ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇. • France (▇▇▇▇▇▇▇ ▇▇▇▇▇▇ and ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇- ▇▇▇▇▇▇▇), • Japan (▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇) • Canada (▇▇▇▇▇▇▇ ▇▇▇▇▇) • In 1993 ▇▇▇▇ ▇▇▇▇▇▇▇▇’▇ team at the University of Utah, working with a database of 200,000 Mormon family groups and most of the 1.6 million descendants of the initial 10,000 Utah settlers, sought to identify the BRCA genes. • ▇▇▇▇▇▇▇▇'▇ group formed Myriad Genetics, Inc with the aim of obtaining the funding needed to complete the research. • Myriad secured funding from ▇▇▇ ▇▇▇▇▇ and Co. • In 1993, ▇▇▇▇▇▇ raised $10 million of which ▇▇▇ ▇▇▇▇▇ contributed $2.8 million over 3 years to search for the genes associated with hereditary breast cancer in return for licensing privileges for diagnostic kits and therapeutic products on BRCA1. • August 12 1994 ▇▇▇▇▇▇ filed a US patent application covering the BRCA1 and on December 2, 1997, the US Patent Office granted Myriad a patent over 47 separate mutations in the BRCA1 gene. • Subsequently, the USPTO granted seven additional patents to Myriad covering the BRCA1 gene and associated diagnostic tests, methods of detecting BRCA1 mutations and the entire sequence of the BRCA1 gene and tools used in their work. • These patents gave ▇▇▇▇▇▇ covered all uses of the BRCA1 gene. International patenting by ▇▇▇▇▇▇ • Canada - 2000 and 2001 patents covering BRCA1 and mutations and diagnostic tests • Europe – 2001 • Australia – 2001 • New Zealand 2001 • Japan 2001 • In 1996 Myriad began marketing its diagnostic tests: (1) the Comprehensive BRCA Analysis, which involved full sequence testing of the BRCA1 and BRCA2 genes (offered at the time at US$2400), (2) the Single Site BRCA Analysis test (offered at US$395.00) Infringement of ▇▇▇▇▇▇’s patents • From May 1998, ▇▇▇▇▇▇ sought to eliminate BRCA testing at competing laboratories by sending cease-and-desist letters. Concerns centred on • the prices charged by Myriad for its screening tests (up to three times those charged by laboratories in Australia, Europ...

Industrial application. An invention shall be considered as susceptible of industrial application if it can be made or used in any kind of industry, including agriculture T 870/04 (BDP1 Phosphatase/MAX- ▇▇▇▇▇▇) T 898/05 (Hematopoietic receptor/ Zymogenetics) T 19/90 (Onco-mouse/Harvard) T 72/04 (Pulp heating/Kvaerner) The effect of licences under patents Fundamentals of infringement claimant Construction of patent specifications Plaintiff/ Grounds for Jursidiction and procedure Defences and remedies Decisions and judgments Burden of proof Liability National approaches The grant of a patent, a supplementary protection certificate (SPC) or a utility model is subject to review as to whether or not the requirements for patentability have been met. Patents are granted by national patent offices or the European Patent Office (EPO) after an examination as to the patentability of the invention. However, not all the relevant prior art or other relevant issues for the assessment of patentability may have been identified by the patent office, or their significance may not have been correctly recognised during examination. Given the potential impact on the public at large of the monopoly which patents and SPCs provide, there are public policy reasons for facilitating the removal of invalid patents from patent registers. Accordingly, a number of judicial means exist across Europe for challenging the validity of patents. Invalidity can be raised in separate invalidity (revocation or cancellation) proceedings (before the EPO, see Article 99 of the European Patent Convention (EPC) for European patents, and/or national decision-making bodies such as courts or patent offices). It can also be raised in most European jurisdictions as a counter-claim or defence in infringement proceedings (“no invalid patent can be infringed”), so that the respective court can revoke the patent (with erga omnes effect) or dismiss the action on invalidity grounds. Such counter-claim and use as a complete defence does not exist in, for example, Germany, Austria and Hungary, which operate a “bifurcated” system. Under this system, erga omnes revocation decisions are given by specialised decision-making bodies rather than the trial courts hearing the infringement case. In German and Austrian infringement proceedings, the infringement courts will only suspend an injunction to await the revocation decision if they believe the likelihood of revocation Differences between bifurcated and non- bifurcated systems to be high (i.e...